DK0624596T3 - Tetrazolderivater af galdesyrer, fremgangsmåde tilderes fremstilling og anvendelse af disse forbindelser som lægemidler - Google Patents

Tetrazolderivater af galdesyrer, fremgangsmåde tilderes fremstilling og anvendelse af disse forbindelser som lægemidler

Info

Publication number
DK0624596T3
DK0624596T3 DK94106848T DK94106848T DK0624596T3 DK 0624596 T3 DK0624596 T3 DK 0624596T3 DK 94106848 T DK94106848 T DK 94106848T DK 94106848 T DK94106848 T DK 94106848T DK 0624596 T3 DK0624596 T3 DK 0624596T3
Authority
DK
Denmark
Prior art keywords
compounds
preparation
drugs
bile acids
tetrazole derivatives
Prior art date
Application number
DK94106848T
Other languages
Danish (da)
English (en)
Inventor
Heiner Dr Glombik
Alfons Dr Enhsen
Werner Dr Dr Kramer
Guenter Dr Wess
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of DK0624596T3 publication Critical patent/DK0624596T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK94106848T 1993-05-08 1994-05-02 Tetrazolderivater af galdesyrer, fremgangsmåde tilderes fremstilling og anvendelse af disse forbindelser som lægemidler DK0624596T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4315368 1993-05-08

Publications (1)

Publication Number Publication Date
DK0624596T3 true DK0624596T3 (da) 1998-10-07

Family

ID=6487579

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94106848T DK0624596T3 (da) 1993-05-08 1994-05-02 Tetrazolderivater af galdesyrer, fremgangsmåde tilderes fremstilling og anvendelse af disse forbindelser som lægemidler

Country Status (19)

Country Link
US (1) US5466815A (enExample)
EP (1) EP0624596B1 (enExample)
JP (1) JP3476157B2 (enExample)
KR (1) KR100333149B1 (enExample)
AT (1) ATE163938T1 (enExample)
AU (1) AU666440B2 (enExample)
CA (1) CA2123048C (enExample)
CY (1) CY2119B1 (enExample)
CZ (1) CZ289515B6 (enExample)
DE (1) DE59405410D1 (enExample)
DK (1) DK0624596T3 (enExample)
ES (1) ES2115096T3 (enExample)
FI (1) FI942075L (enExample)
GR (1) GR3026496T3 (enExample)
HU (1) HU217439B (enExample)
IL (1) IL109581A (enExample)
NO (1) NO304795B1 (enExample)
NZ (1) NZ260469A (enExample)
TW (1) TW289757B (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0624593A3 (de) * 1993-05-08 1995-06-07 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
TW289020B (enExample) * 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
US6323190B1 (en) 1998-07-31 2001-11-27 The Univeristy Of Georgia Research Foundation, Inc. Estrogen mimetics lacking reproductive tract effects
AU775630B2 (en) 1999-04-30 2004-08-05 Arch Development Corporation Steroid derivatives
US7086134B2 (en) * 2000-08-07 2006-08-08 Shipley Company, L.L.C. Alignment apparatus and method for aligning stacked devices
CA2438221A1 (en) * 2001-02-08 2002-08-15 The University Of Chicago Steroidal derivatives
DE60223020T2 (de) * 2001-05-03 2008-07-24 The University Of Chicago, Chicago Leber x rezeptoragonisten
US7078396B2 (en) * 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
US20070197484A1 (en) * 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
US6816317B2 (en) * 2002-01-31 2004-11-09 Lightel Technologies Inc. Collimator for ready fitting to an optical device with precise optical alignment without need for adjusting positions or angles to compensate for offsets or deviations during optical device assembly and method of making same
CA2482195A1 (en) * 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
CN101005857A (zh) 2004-07-08 2007-07-25 诺和诺德公司 多肽延长标记
US20070032464A1 (en) * 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
US7960439B1 (en) 2006-06-12 2011-06-14 Iowa State University Research Foundation, Inc. Environmentally sensitive foldable oligomers
US8829213B2 (en) * 2009-07-29 2014-09-09 The University Of Chicago Liver X receptor agonists
TR201810984T4 (tr) 2010-11-04 2018-09-21 Albireo Ab Karaciğer hastalıklarının tedavisi için IBAT inhibitörleri.
EP2637646B1 (en) 2010-11-08 2016-05-11 Albireo AB A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
AU2015343025A1 (en) 2014-11-06 2017-06-08 Enanta Pharmaceuticals, Inc. Bile acid analogs an FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CN107231795A (zh) 2014-11-26 2017-10-03 英安塔制药有限公司 作为fxr/tgr5激动剂的胆汁酸类似物及其使用方法
HK1245100A1 (zh) * 2015-02-11 2018-08-24 Enanta Pharmaceuticals, Inc. 作为fxr/tgr5激动剂的胆汁酸类似物及其使用方法
WO2016161003A1 (en) 2015-03-31 2016-10-06 Enanta Phamraceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2016173397A1 (zh) * 2015-04-28 2016-11-03 上海翰森生物医药科技有限公司 胆酸衍生物及其制备方法和医药用途
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
WO2017138877A1 (en) 2016-02-09 2017-08-17 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
JP6954927B2 (ja) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ 経口コレスチラミン製剤及びその使用
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
US10584145B2 (en) 2016-11-29 2020-03-10 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
JP7136802B2 (ja) 2017-04-07 2022-09-13 エナンタ ファーマシューティカルズ インコーポレイテッド スルホニルカルバマート胆汁酸誘導体の調製のためのプロセス
WO2019032026A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
WO2019032027A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
CA3100113A1 (en) 2018-06-05 2019-12-12 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
KR20210024033A (ko) 2018-06-20 2021-03-04 알비레오 에이비 오데빅시바트의 약학 제제
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
EP3911331A4 (en) * 2019-01-14 2023-01-18 Beijing Xuanyi Pharmasciences Co., Ltd. TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF
WO2020161216A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
HUE060905T2 (hu) 2019-02-06 2023-04-28 Albireo Ab Benzotiadiazepin vegyületek és azok alkalmazása epesav modulátorként
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US11358143B2 (en) * 2019-03-19 2022-06-14 Siemens Healthcare Diagnostics Inc. Compositions, devices, and methods of mitigating lipoprotein interference in in vitro diagnostic assays for hydrophobic analytes
AR120682A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar
EP4069361B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
ES3029063T3 (en) 2019-12-04 2025-06-23 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
BR112022010505A2 (pt) 2019-12-04 2022-09-06 Albireo Ab Compostos de benzotia(di)azepina e seu uso como moduladores do ácido biliar
TWI871392B (zh) 2019-12-04 2025-02-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
CA3158276A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
PT4069360T (pt) 2019-12-04 2024-03-06 Albireo Ab Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar
TWI867107B (zh) 2019-12-04 2024-12-21 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CN116157389B (zh) 2020-08-03 2026-02-10 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
WO2022117778A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
JP2025516153A (ja) 2022-04-22 2025-05-27 アルビレオ・アクチボラグ Ａｓｂｔ阻害剤の皮下投与
JP2025524362A (ja) 2022-06-09 2025-07-30 アルビレオ・アクチボラグ 肝炎の処置
CN119256000A (zh) * 2022-06-09 2025-01-03 山东绿叶制药有限公司 19-去甲c3,3-二取代的c21-氮杂环取代类固醇及其使用方法
CA3259103A1 (en) 2022-07-05 2024-01-11 Albireo Ab Benzothia (di)azepine compounds and their use as bile acid modulators
KR20250110930A (ko) 2022-12-09 2025-07-21 알비레오 에이비 신장 질병 치료용 asbt 억제제
WO2025119319A1 (zh) * 2023-12-08 2025-06-12 山东绿叶制药有限公司 一种gabaa受体调节剂的晶型及其制备方法和应用
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
IL100240A (en) * 1990-12-06 1995-10-31 Hoechst Ag Bile acid derivatives process for their preparation and use of these compounds as pharmaceuticals

Also Published As

Publication number Publication date
IL109581A0 (en) 1994-08-26
GR3026496T3 (en) 1998-07-31
AU6194794A (en) 1994-11-10
CA2123048C (en) 2005-11-29
TW289757B (enExample) 1996-11-01
IL109581A (en) 1998-03-10
ES2115096T3 (es) 1998-06-16
EP0624596A3 (de) 1995-06-07
HU9401443D0 (en) 1994-08-29
JP3476157B2 (ja) 2003-12-10
DE59405410D1 (de) 1998-04-16
FI942075A0 (fi) 1994-05-05
NO941677L (no) 1994-11-09
FI942075A7 (fi) 1994-11-09
CY2119B1 (en) 2002-04-26
CA2123048A1 (en) 1994-11-09
FI942075L (fi) 1994-11-09
EP0624596A2 (de) 1994-11-17
HU217439B (hu) 2000-01-28
US5466815A (en) 1995-11-14
NO304795B1 (no) 1999-02-15
AU666440B2 (en) 1996-02-08
ATE163938T1 (de) 1998-03-15
HUT67390A (en) 1995-04-28
JPH06329695A (ja) 1994-11-29
KR100333149B1 (ko) 2002-09-19
EP0624596B1 (de) 1998-03-11
NZ260469A (en) 1995-03-28
CZ289515B6 (cs) 2002-02-13
NO941677D0 (no) 1994-05-06
CZ113594A3 (en) 1994-12-15

Similar Documents

Publication Publication Date Title
DK0624596T3 (da) Tetrazolderivater af galdesyrer, fremgangsmåde tilderes fremstilling og anvendelse af disse forbindelser som lægemidler
DK0624594T3 (da) Monomere galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemiddel
TW289020B (enExample)
FI883249A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 3-desmetyylimevalonihappojohdannaisten valmistamiseksi
DK0573848T3 (da) Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler
FI96204C (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten yhdisteiden valmistamiseksi
NO924921D0 (no) Polyaspartamidderivater som adsorbsjonsmiddel for gallesyrer, polyaspartamidderivat lastet med gallesyrer og fremgangsmaater for fremstilling av disse, samt deres anvendelse som legemiddel
DK383388A (da) 3-demethyl-4-fluor-mevalonsyrederivater, deres fremstilling, farmaceutiske praeparater deraf, deres anvendelse og mellemprodukter til deres fremstilling
AU1264488A (en) Substituted pyridine-2,4-dicarboxylic acid derivatives, processes for their preparation, the use thereof and medicaments based on these compounds
DE69226432D1 (de) 2-spirocyclopropyl 4-acylcephalosporine und verfahren zu ihrer herstellung
IT1282286B1 (it) Seco-d steroidi sul sistema cardiovascolare, processi per la loro preparazione e composizioni farmaceutiche che li contengono.
DE3862404D1 (de) Benzylaminoaryl-dihydropyridinelactone, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.